Pharmaceuticals UK

UK Anti-Obesity Drugs Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

UK Anti-Obesity Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route of Administration, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

UK · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $343.2 Mn Placeholder estimate
Estimate 2025 $432.1 Mn 2.4% of the global market
Projected 2034 $3.43 Bn 694.8% Adds $3.00 Bn over 9 forecast years
CAGR 2025–2034 25.9% Faster than 96% of 186 Pharmaceuticals markets here
Key players 6 +1
  • UK is 2.4% of the global market.
  • In Europe, the largest is Germany at $597.9 Mn.
  • Fastest growing: Russia at 28.4% a year.
  • UK ranks 4th of 6 by size in Europe.

Market size projection

UK

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$3.00 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Anti-Obesity Drugs Market market size by year, UK
YearMarket sizeChange that yearSince 2025
2024 (estimate) $343.2 Mn — —
2025 (base) $432.1 Mn +$88.9 Mn —
2026 (forecast) $544.0 Mn +$111.9 Mn +25.9%
2027 (forecast) $684.9 Mn +$140.9 Mn +58.5%
2028 (forecast) $862.3 Mn +$177.4 Mn +99.6%
2029 (forecast) $1.09 Bn +$223.3 Mn +151.2%
2030 (forecast) $1.37 Bn +$281.2 Mn +216.3%
2031 (forecast) $1.72 Bn +$354.0 Mn +298.2%
2032 (forecast) $2.17 Bn +$445.7 Mn +401.4%
2033 (forecast) $2.73 Bn +$561.1 Mn +531.3%
2034 (forecast) $3.43 Bn +$706.5 Mn +694.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

UK Anti-Obesity Drugs Market Analysis at a glance
Market size, 2025$432.1 Mn placeholder estimate
Forecast, 2034$3.43 Bn placeholder estimate
Growth (CAGR), 2025–203425.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, route of administration and end user (see all)
Key playersNovo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim GmbH, Amgen Inc., Currax Pharmaceuticals and 1 more (see all)
Regulator in the UKMHRASource: Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
Active clinical trials14 in the UKSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The UK Anti-Obesity Drugs Market Analysis Executive Summary

Anti-obesity drugs help people with obesity lose weight and keep it off by reducing appetite, increasing fullness or blocking fat absorption.

Key segments of the anti-Obesity Drugs market include drug class (GLP-1 Agonists, Dual and Triple Agonists and Lipase Inhibitors) and route of administration (Injectable and Oral).

Bar chart: UK Anti-Obesity Drugs market size, 2024–2034, placeholder estimates. $343.2 Mn in 2024, $432.1 Mn in 2025 and $3.43 Bn in 2034, 25.9% CAGR.
UK Anti-Obesity Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

UK Anti-Obesity Drugs Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the anti-Obesity Drugs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the anti-Obesity Drugs market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the anti-Obesity Drugs market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Anti-Obesity Drugs Market in the UK

The anti-Obesity Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Anti-Obesity Drugs Market in the UK

Anti-Obesity Drugs in the UK: rules, payment and research

The Medicines and Healthcare products Regulatory Agency (MHRA) licenses medicines in the UK.⁠[1] The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund.⁠[2] ClinicalTrials.gov lists 14 studies on Anti-Obesity Drugs that are recruiting, active or about to start in the UK.⁠[3] Obesity (adults): 27.4% of adults in 2024, the latest WHO figure for the UK.⁠[4]

[1] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[2] National Institute for Health and Care Excellence. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 22 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for anti-Obesity Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in the UK.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Anti-Obesity Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 22 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Anti-Obesity Drugs in context

The UK compared

  • Obesity (adults): 27.4% of adults (2024). World: 16.2% of adults (2024). 2nd highest of the 13 countries we cover in Europe.[1]
  • Health spending per person: 5,860 US$ per person (2024). World: 1,317 US$ per person (2023). 7th highest of the 13 countries we cover in Europe.[2]
  • Doctors: 3.30 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 11th highest of the 13 countries we cover in Europe.[3]

[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 21 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.

Free data on this topic

Inside the UK

Quick answers

Frequently asked questions

How big is the Anti-Obesity Drugs market in the UK?
Placeholder estimate: about $432.1 Mn in 2025, rising to about $3.43 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Anti-Obesity Drugs market in the UK growing?
Placeholder estimate: about 25.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Anti-Obesity Drugs market report cover?
The report splits the market by drug class (GLP-1 Agonists, Dual and Triple Agonists, Lipase Inhibitors, Combination Drugs), route of administration (Injectable, Oral) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Anti-Obesity Drugs market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim GmbH, Amgen Inc., Currax Pharmaceuticals and Rhythm Pharmaceuticals.
What is driving the Anti-Obesity Drugs market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the anti-Obesity Drugs market.
Who regulates Anti-Obesity Drugs in the UK?
The Medicines and Healthcare products Regulatory Agency (MHRA) licenses medicines in the UK. Source: Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
How is healthcare paid for in the UK?
The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund. Source: National Institute for Health and Care Excellence. Checked 14 Nov 2026.
How many clinical trials on Anti-Obesity Drugs are running in the UK?
14 studies are recruiting, active or about to start in the UK, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
What does WHO report for the UK?
Obesity (adults): 27.4% of adults in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 22 Nov 2026.
How many people in the UK are 65 or older?
19.7% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 22 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in UK

See all

Related on obesity and diabetes

See the topic